Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LOEWS CORPL · Entity 3231 | DIRECTOR EMERITUS | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LOEWS CORP
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,165 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 102 · Balance 22,165 F1: Represents quarterly grant of common stock in respect of director compensation (prorated for service through the date of his retirement as a director) under the Loews Corporation 2025 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents quarterly grant of common stock in respect of director compensation (prorated for service through the date of his retirement as a director) under the Loews Corporation 2025 Incentive Compensation Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 2,865,637 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | IndirectBy wife | 0 |
Reported balance
After 2021-06-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-06-02 · Disposition to issuer · Disposed 374,112 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | IndirectBy custodial accounts for benefit of grandchildren | 0 |
Reported balance
After 2021-06-02 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-06-02 · Disposition to issuer · Disposed 185,928 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | IndirectShares held by Dico Group, Inc. | 0 |
Reported balance
After 2021-06-02 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-06-02 · Disposition to issuer · Disposed 29,430 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 5, 2023 20:08 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $46.99 | $105,727.50 |
DisclosureSEC source: 0000060086-23-000162 · wk-form4_1693944504.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:55 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $44.44 | $0.00 |
DisclosureSEC source: 0000060086-23-000124 · wk-form4_1685739303.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2022. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:55 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 474 | $56.30 | $26,686.20 |
DisclosureSEC source: 0000060086-23-000124 · wk-form4_1685739303.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,200 F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2022. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $56.19 and $56.39. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:55 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,776 | $56.28 | $99,953.28 |
DisclosureSEC source: 0000060086-23-000124 · wk-form4_1685739303.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,674 F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:55 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $44.44 | $99,990.00 |
DisclosureSEC source: 0000060086-23-000124 · wk-form4_1685739303.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2022. Read SEC document |
| May 10, 2023 Filed May 10, 2023 19:52 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000108 · wf-form4_168374835014517.xml · derivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 10, 2022, the Reporting Person was granted 1,567 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F4 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 10, 2022, the Reporting Person was granted 1,567 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 10, 2023 Filed May 10, 2023 19:52 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000108 · wf-form4_168374835014517.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| May 09, 2023 Filed May 10, 2023 19:52 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000108 · wf-form4_168374835014517.xml · derivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,706 Underlying: Common Stock · 1,706 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest on May 9, 2024. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F3 · derivative.expiration_date: The RSUs vest on May 9, 2024. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:51 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $43.89 | $0.00 |
DisclosureSEC source: 0000060086-23-000077 · wf-form4_167777948696607.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:51 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 625 | $60.98 | $38,112.50 |
DisclosureSEC source: 0000060086-23-000077 · wf-form4_167777948696607.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,633 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $60.75 and $60.98. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:51 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,625 | $60.75 | $98,718.75 |
DisclosureSEC source: 0000060086-23-000077 · wf-form4_167777948696607.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,258 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:51 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $43.89 | $98,752.50 |
DisclosureSEC source: 0000060086-23-000077 · wf-form4_167777948696607.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:34 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $40.47 | $0.00 |
DisclosureSEC source: 0000060086-22-000130 · wf-form4_167000604606590.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:34 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 698 | $58.07 | $40,532.86 |
DisclosureSEC source: 0000060086-22-000130 · wf-form4_167000604606590.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,633 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $57.83 and $58.66. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:34 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,552 | $58.66 | $91,040.32 |
DisclosureSEC source: 0000060086-22-000130 · wf-form4_167000604606590.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,331 Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:34 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $40.47 | $91,057.50 |
DisclosureSEC source: 0000060086-22-000130 · wf-form4_167000604606590.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $41.14 | $0.00 |
DisclosureSEC source: 0000060086-22-000088 · wf-form4_166247882751458.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 572 | $54.88 | $31,391.36 |
DisclosureSEC source: 0000060086-22-000088 · wf-form4_166247882751458.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,633 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $54.88 and $55.16. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,678 | $55.16 | $92,558.48 |
DisclosureSEC source: 0000060086-22-000088 · wf-form4_166247882751458.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,205 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $41.14 | $92,565.00 |
DisclosureSEC source: 0000060086-22-000088 · wf-form4_166247882751458.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:43 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0000060086-22-000062 · wf-form4_165419179937297.xml · derivative · entry 5 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:43 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 15 | $65.48 | $982.20 |
DisclosureSEC source: 0000060086-22-000062 · wf-form4_165419179937297.xml · nonDerivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,633 Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:43 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 868 | $64.35 | $55,855.80 |
DisclosureSEC source: 0000060086-22-000062 · wf-form4_165419179937297.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $64.20 and $64.51. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:43 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,367 | $65.48 | $89,511.16 |
DisclosureSEC source: 0000060086-22-000062 · wf-form4_165419179937297.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,516 Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:43 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $39.80 | $89,550.00 |
DisclosureSEC source: 0000060086-22-000062 · wf-form4_165419179937297.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2022 Filed May 11, 2022 19:52 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-22-000037 · wf-form4_165229876155979.xml · derivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 11, 2021, the Reporting Person was granted 1,725 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F4 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 11, 2021, the Reporting Person was granted 1,725 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 11, 2022 Filed May 11, 2022 19:52 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-22-000037 · wf-form4_165229876155979.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| May 10, 2022 Filed May 11, 2022 19:52 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-22-000037 · wf-form4_165229876155979.xml · derivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,567 Underlying: Common Stock · 1,567 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest on May 10, 2023. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F3 · derivative.expiration_date: The RSUs vest on May 10, 2023. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:52 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $39.41 | $0.00 |
DisclosureSEC source: 0001567619-22-006060 · doc1.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:52 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 797 | $59.91 | $47,748.27 |
DisclosureSEC source: 0001567619-22-006060 · doc1.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,908 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $59.88 and $61.02. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:52 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,453 | $61.02 | $88,662.06 |
DisclosureSEC source: 0001567619-22-006060 · doc1.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,705 Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:52 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $39.41 | $88,672.50 |
DisclosureSEC source: 0001567619-22-006060 · doc1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 18:00 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $37.78 | $0.00 |
DisclosureSEC source: 0001567619-21-021433 · doc1.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 18:00 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 459 | $54.70 | $25,107.30 |
DisclosureSEC source: 0001567619-21-021433 · doc1.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,908 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $54.43 and $54.71. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 18:00 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,041 | $54.43 | $56,661.63 |
DisclosureSEC source: 0001567619-21-021433 · doc1.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,367 Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 18:00 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,500 | $37.78 | $56,670.00 |
DisclosureSEC source: 0001567619-21-021433 · doc1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:43 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $35.04 | $0.00 |
DisclosureSEC source: 0001567619-21-016573 · doc1.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:43 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 561 | $55.62 | $31,202.82 |
DisclosureSEC source: 0001567619-21-016573 · doc1.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,908 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $55.62 and $55.97. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:43 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 939 | $55.97 | $52,555.83 |
DisclosureSEC source: 0001567619-21-016573 · doc1.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,469 Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:43 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,500 | $35.04 | $52,560.00 |
DisclosureSEC source: 0001567619-21-016573 · doc1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:22 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 29,430 | $80.59 | $2,371,763.70 |
DisclosureSEC source: 0001104659-21-075844 · tm2118222-4_4seq1.xml · nonDerivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Dico Group, Inc. Disclosed balance after: 0 F1 · kind: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · price: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:22 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 185,928 | $80.59 | $14,983,937.52 |
DisclosureSEC source: 0001104659-21-075844 · tm2118222-4_4seq1.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By custodial accounts for benefit of grandchildren Disclosed balance after: 0 F1 · kind: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · price: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:22 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 374,112 | $80.59 | $30,149,686.08 |
DisclosureSEC source: 0001104659-21-075844 · tm2118222-4_4seq1.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 0 F1 · kind: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · price: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:22 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 2,865,637 | $80.59 | $230,941,685.83 |
DisclosureSEC source: 0001104659-21-075844 · tm2118222-4_4seq1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · price: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:47 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $42.02 | $0.00 |
DisclosureSEC source: 0001567619-21-011500 · doc1.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:47 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 429 | $58.63 | $25,152.27 |
DisclosureSEC source: 0001567619-21-011500 · doc1.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,908 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $58.62 and $58.84. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:47 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,071 | $58.84 | $63,017.64 |
DisclosureSEC source: 0001567619-21-011500 · doc1.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,337 Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:47 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,500 | $42.02 | $63,030.00 |
DisclosureSEC source: 0001567619-21-011500 · doc1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 12, 2021 15:07 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 3,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-009642 · doc1.xml · derivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 12, 2020, the Reporting Person was granted 3,292 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F4 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 12, 2020, the Reporting Person was granted 3,292 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 12, 2021 Filed May 12, 2021 15:07 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 3,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-009642 · doc1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.